Sarcosine for Schizophrenia (adjunct) and Sarcosine
Each entry’s own grades, side by side. A grade says how strong the evidence is for one outcome — it does not rank one entry over the other.
Evidence brief
Sarcosine for Schizophrenia (adjunct)
Evidence grade B — Add-on
Grade B1 graded outcomerevised Jul 10, 2026
Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.
Compound or practice
Sarcosine
An NMDA co-agonist amino acid with real add-on evidence in schizophrenia — a niche, mechanism-driven mood/cognition agent.
Grade C2 graded outcomesrevised Jul 10, 2026
A structured monograph in Prometheus's bundled library. Its grades are the monograph's own reading of the evidence, not a peer-reviewed review.
Graded in both
Outcomes are matched by name. Two entries can describe the same outcome in different words, so one listed further down may still be graded in the other.
| Outcome | Sarcosine for Schizophrenia (adjunct) | Sarcosine |
|---|---|---|
| Schizophrenia (adjunct) | Evidence grade BSmall effectmixedAdd-on | Evidence grade BSmall effectmixedAdd-on |
Graded only in Sarcosine for Schizophrenia (adjunct)
None — every outcome it grades is graded in both.
Graded only in Sarcosine
- OCD / depression Small effectEvidence grade C
What each entry says about the other
- Sarcosine for Schizophrenia (adjunct)’s entry · Goes with: Read the full Sarcosine monograph
Both columns are read from the entries as they stand in this library. A comparison is not advice to take either one, and it is no substitute for a clinician who knows the person.